骨髓发育不良症候群治疗市场－全球产业规模、份额、趋势、机会、预测：按治疗类型、最终用户、地区和竞争格局划分，2021-2031年

全球骨髓发育不良症候群(MDS) 治疗市场预计将从 2025 年的 30.4 亿美元成长到 2031 年的 43.3 亿美元，复合年增长率为 6.07%。

骨髓增生异常综合症（MDS）的治疗方法多种多样，从去甲基化药物和免疫调节剂到造血干细胞移植，旨在恢復正常的骨髓功能并防止其进展为急性骨髓性白血病。全球人口老化是推动此疾病发展的主要因素。这些骨髓功能障碍疾病通常与老龄化有关，而诊断技术的进步正在发现以前未被发现的病例，从而确保了对医疗干预的持续需求。

儘管存在这些有利条件，但该疾病的临床表现多样性使得准确诊断和标靶治疗的选择变得困难，为市场发展带来了重大障碍。这种复杂性往往导致患者治疗依从性低，并为患者管理带来许多挑战。例如，根据MDS联盟2024年报告，45%的患者不清楚自己的MDS亚型，这种诊断上的不确定性阻碍了先进疗法的有效应用，并限制了该专科领域的潜在增长。

市场驱动因素

一系列创新疗法的涌现正从根本上改变全球骨髓增生异常综合症（MDS）的治疗市场。治疗标准正从单纯的支持性治疗转向缓解疾病疗法。研发人员正优先研究端粒酶抑制剂和其他新型作用机制，以克服传统促红血球生成剂的不足，尤其是在输血依赖型患者身上。鑑于该疾病预后不良，这项创新至关重要。美国临床肿瘤学会（ASCO）于2024年3月报告称，MDS的5年相对存活率约为37%。监管方面的进展也为此发展提供了支持；例如，Geron公司于2024年6月宣布，FDA已核准Litero（伊美替司他）。 IMerge III期临床试验表明，伊美替司他治疗可使39.8%的患者在至少8週内摆脱红血球输注依赖。

同时，标靶治疗的兴起正在推动市场成长，尤其是在一线治疗领域，因为它们能够更精准地治疗特定疾病亚型。这些疗法针对特定的生物路径或成熟障碍，与传统的特异性疗法相比，其应用日益广泛，并创造了显着的商业性价值。这一转变也体现在主要企业的财务表现中。 2024年10月，百时美施贵宝公司报告称，其Reblozyl®的全球销售额成长了80%，达到4.47亿美元。这主要得益于第一线MDS治疗的强劲需求，也显示市场正在围绕那些与传统治疗方法相比疗效更佳的高价值药物疗法进行整合。

市场挑战

骨髓发育不良症候群综合症 (MDS) 固有的临床异质性是全球治疗市场成长的主要阻碍因素。由于疾病表现出不同的生物学特征和进展速度，医生往往难以做出准确诊断并确定最佳治疗策略。这种差异性导致治疗延误和次优治疗方案的选择，阻碍了标靶治疗的应用，并给寻求广泛分销针对特定生物学亚型药物的製造商设置了障碍。

这种诊断的复杂性导致患者群体分散，并限制了先进疗法的获利能力。由于缺乏准确的分类，患者往往被分配到一般支持治疗，而不是接受高价值的积极治疗。美国癌症协会估计，到2025年，美国将新增13,000例骨髓增生异常综合症（MDS）病例，但由于缺乏标准化的疾病表现，诊断的不确定性限制了更有效医疗干预措施的持续应用，市场也无法充分满足这一需求。

市场趋势

口服低甲基化药物的出现显着改变了治疗环境，将治疗方式从静脉注射转变为居家照护。这一趋势提供了一种更便捷的选择，减轻了长期肠外给药带来的后勤挑战，并有助于提高治疗依从性，减少住院次数。真实世界的临床数据支持这种转变的安全性。根据2025年11月美国血液学会（ASH）的摘要，接受口服Decitabine和塞达扎瑞联合治疗的患者在前两个疗程中发烧性嗜中性白血球低下症症的发生率显着降低（17%），这表明与肠外给药组（55%）相比，住院风险可能降低。

另一方面，联合治疗的临床试验在市场上迅速增加，製药公司正在检验具有新型作用机制的药物（例如BCL-2抑制剂）与去甲基化药物联合使用，以克服单药治疗的限制。这项研究旨在透过协同作用提高高风险族群的生存率，但获得具有统计意义的临床结果仍然困难重重。例如，2025年6月，艾伯维公司宣布其针对新诊断高风险患者的III期主要临床试验「VERONA」（该试验将维奈托克与Azacitidine联合使用）未能达到其主要终点－总生存期，风险比为0.908。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球骨髓发育不良症候群（MDS）治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依类型分类的治疗方法（干细胞移植、免疫疗法、化疗、免疫调节药物、抗贫血药物、其他）
  • 依最终使用者（医院/诊所、门诊中心、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美骨髓发育不良症候群（MDS）治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲骨髓发育不良症候群（MDS）治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区骨髓发育不良症候群（MDS）治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲骨髓发育不良症候群（MDS）治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲骨髓发育不良症候群（MDS）治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球骨髓发育不良症候群（MDS）治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• AbbVie Inc.
• Accord Healthcare Limited
• Bristol-Myers Squibb Company
• Jazz Pharmaceuticals Inc.
• Novartis AG
• Lupin Limited
• Otsuka America Pharmaceutical Inc.
• Takeda Pharmaceutical Company Limited
• Astex Therapeutics Limited
• Pfizer Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Myelodysplastic Syndrome (MDS) Treatment Market is projected to expand from USD 3.04 Billion in 2025 to USD 4.33 Billion by 2031, reflecting a compound annual growth rate of 6.07%. Treatments for MDS, which range from hypomethylating agents and immunomodulators to hematopoietic stem cell transplantation, aim to reinstate normal bone marrow activity and halt the progression to acute myeloid leukemia. A key factor driving this growth is the aging global population, as these bone marrow failure disorders are frequently associated with advancing age, while improved diagnostic techniques are uncovering previously undetected cases, ensuring a steady demand for medical interventions.

Despite these favorable conditions, the market confronts substantial hurdles due to the clinical heterogeneity of the disease, which makes accurate diagnosis and targeted therapy selection difficult. This complexity often results in poor treatment adherence and significant management challenges for patients. For example, the MDS Alliance reported in 2024 that 45% of patients were unaware of their specific MDS subtype, a lack of diagnostic clarity that limits the effective use of advanced therapies and restricts the potential growth of the specialized treatment sector.

Market Driver

A strong pipeline of innovative therapeutic agents is fundamentally transforming the Global MDS Treatment Market, moving the standard of care from merely supportive measures to disease-modifying interventions. Developers are prioritizing telomerase inhibitors and other new mechanisms to overcome the shortcomings of traditional erythropoiesis-stimulating agents, especially for patients dependent on transfusions. This innovation is vital given the disease's poor prognosis; the American Society of Clinical Oncology noted in March 2024 that the 5-year relative survival rate is around 37%. Regulatory successes underscore this progress, such as Geron Corporation's June 2024 announcement regarding the FDA approval of Rytelo, where the IMerge Phase 3 trial showed a 39.8% red blood cell transfusion independence rate for at least eight weeks with imetelstat.

In parallel, the rise of targeted and immunomodulatory therapies is fueling market growth by allowing for more precise treatment of specific disease subtypes, particularly in first-line settings. These therapies, which address specific biological pathways and maturation defects, are seeing increased adoption and generating significant commercial value over older, non-specific treatments. This shift is reflected in the financial results of major players; Bristol Myers Squibb reported in October 2024 that worldwide revenues for Reblozyl jumped 80% to $447 million, driven by robust demand in first-line MDS treatment, indicating a market consolidation around high-value pharmacotherapies that deliver better outcomes than traditional care.

Market Challenge

The clinical heterogeneity inherent in Myelodysplastic Syndromes poses a major constraint on the growth of the global treatment market. Since the disease manifests with diverse biological features and progression speeds, physicians often struggle to pinpoint accurate diagnoses and determine the best therapeutic courses. This variability frequently results in delayed treatment or the choice of suboptimal management plans, thereby dampening the utilization of targeted pharmacotherapies and creating barriers for manufacturers attempting to widely distribute drugs tailored to specific biological subtypes.

Such diagnostic complexity fragments the patient base and curbs the revenue potential for advanced treatments. Without precise classification, patients are frequently assigned to general supportive care rather than receiving high-value active therapies. Although the American Cancer Society estimates that 13,000 new MDS cases will be diagnosed in the United States in 2025, the absence of a standardized disease presentation prevents the market from fully addressing this demand, as diagnostic uncertainty limits the consistent prescription of premium medical interventions.

Market Trends

The shift toward Oral Hypomethylating Agents is significantly reshaping the treatment landscape by moving care from intravenous infusions to home-based regimens. This trend mitigates the logistical challenges of chronic parenteral therapies, providing a more convenient option that aids adherence and decreases the frequency of clinic visits. Real-world data supports the safety of this transition; an abstract from the American Society of Hematology in November 2025 revealed that patients on oral decitabine-cedazuridine had a notably lower incidence of febrile neutropenia during the first two cycles-17% compared to 55% for those on parenteral agents-highlighting the potential for fewer hospitalizations.

At the same time, the market is characterized by a surge in Combination Therapy Clinical Trials, where pharmaceutical companies are testing hypomethylating agents paired with novel mechanisms like BCL-2 inhibition to surpass the efficacy limits of monotherapy. While this research aims to enhance survival in higher-risk groups through synergistic pathways, achieving statistically significant clinical results remains difficult. For instance, AbbVie announced in June 2025 that the pivotal Phase 3 VERONA trial, testing venetoclax combined with azacitidine in newly diagnosed higher-risk patients, failed to meet its primary overall survival endpoint, showing a hazard ratio of 0.908.

Key Market Players

• AbbVie Inc.
• Accord Healthcare Limited
• Bristol-Myers Squibb Company
• Jazz Pharmaceuticals Inc.
• Novartis AG
• Lupin Limited
• Otsuka America Pharmaceutical Inc.
• Takeda Pharmaceutical Company Limited
• Astex Therapeutics Limited
• Pfizer Inc.

Report Scope

In this report, the Global Myelodysplastic Syndrome (MDS) Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Myelodysplastic Syndrome (MDS) Treatment Market, By Treatment Type

• Stem Cell Transplant
• Immune Treatments
• Chemotherapy
• Immunomodulatory Drugs
• Anti-anemics
• Others

Myelodysplastic Syndrome (MDS) Treatment Market, By End User

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Myelodysplastic Syndrome (MDS) Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Myelodysplastic Syndrome (MDS) Treatment Market.

Available Customizations:

Global Myelodysplastic Syndrome (MDS) Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Myelodysplastic Syndrome (MDS) Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Stem Cell Transplant, Immune Treatments, Chemotherapy, Immunomodulatory Drugs, Anti-anemics, Others)
  • 5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Myelodysplastic Syndrome (MDS) Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Myelodysplastic Syndrome (MDS) Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By End User
  • 6.3.2. Canada Myelodysplastic Syndrome (MDS) Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By End User
  • 6.3.3. Mexico Myelodysplastic Syndrome (MDS) Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By End User

7. Europe Myelodysplastic Syndrome (MDS) Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Myelodysplastic Syndrome (MDS) Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By End User
  • 7.3.2. France Myelodysplastic Syndrome (MDS) Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By End User
  • 7.3.3. United Kingdom Myelodysplastic Syndrome (MDS) Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By End User
  • 7.3.4. Italy Myelodysplastic Syndrome (MDS) Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By End User
  • 7.3.5. Spain Myelodysplastic Syndrome (MDS) Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By End User

8. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Myelodysplastic Syndrome (MDS) Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By End User
  • 8.3.2. India Myelodysplastic Syndrome (MDS) Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By End User
  • 8.3.3. Japan Myelodysplastic Syndrome (MDS) Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By End User
  • 8.3.4. South Korea Myelodysplastic Syndrome (MDS) Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment Type
      • 8.3.4.2.2. By End User
  • 8.3.5. Australia Myelodysplastic Syndrome (MDS) Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment Type
      • 8.3.5.2.2. By End User

9. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Myelodysplastic Syndrome (MDS) Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By End User
  • 9.3.2. UAE Myelodysplastic Syndrome (MDS) Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By End User
  • 9.3.3. South Africa Myelodysplastic Syndrome (MDS) Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By End User

10. South America Myelodysplastic Syndrome (MDS) Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Myelodysplastic Syndrome (MDS) Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By End User
  • 10.3.2. Colombia Myelodysplastic Syndrome (MDS) Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By End User
  • 10.3.3. Argentina Myelodysplastic Syndrome (MDS) Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Myelodysplastic Syndrome (MDS) Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AbbVie Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Accord Healthcare Limited
• 15.3. Bristol-Myers Squibb Company
• 15.4. Jazz Pharmaceuticals Inc.
• 15.5. Novartis AG
• 15.6. Lupin Limited
• 15.7. Otsuka America Pharmaceutical Inc.
• 15.8. Takeda Pharmaceutical Company Limited
• 15.9. Astex Therapeutics Limited
• 15.10. Pfizer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer